Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
36.07
-0.83 (-2.25%)
At close: Sep 5, 2025, 4:00 PM
36.01
-0.06 (-0.17%)
After-hours: Sep 5, 2025, 5:46 PM EDT
Royalty Pharma Revenue
Royalty Pharma had revenue of $578.67M in the quarter ending June 30, 2025, with 7.71% growth. This brings the company's revenue in the last twelve months to $2.31B, up 3.02% year-over-year. In the year 2024, Royalty Pharma had annual revenue of $2.26B, down -3.86%.
Revenue (ttm)
$2.31B
Revenue Growth
+3.02%
P/S Ratio
6.85
Revenue / Employee
$23,285,283
Employees
99
Market Cap
21.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.26B | -90.98M | -3.86% |
| Dec 31, 2023 | 2.35B | 117.34M | 5.24% |
| Dec 31, 2022 | 2.24B | -52.25M | -2.28% |
| Dec 31, 2021 | 2.29B | 167.11M | 7.87% |
| Dec 31, 2020 | 2.12B | 308.10M | 16.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RPRX News
- 3 days ago - Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 4 days ago - Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes - GlobeNewsWire
- 5 days ago - Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - GlobeNewsWire
- 5 days ago - Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - GlobeNewsWire
- 13 days ago - Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million - Reuters
- 13 days ago - Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million - GlobeNewsWire
- 13 days ago - BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million - Business Wire
- 25 days ago - Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - GlobeNewsWire